OPTI.LSE OptiBiotix Health Plc
- Market cap
- GBX 5.78M
- P/E
- -
- P/B
- 1.27x
- ROE
- -133.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is OPTI.LSE undervalued?
Graham numberThe Graham number of OptiBiotix Health Plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
OptiBiotix Health Plc fundamental analysis
No fundamental analysis for OptiBiotix Health Plc yet.
OptiBiotix Health Plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About OptiBiotix Health Plc
OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential health benefits. Its first-generation products include Slimbiome, which offers …
Full company profileOptiBiotix Health Plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
OptiBiotix Health Plc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 288K | 191K | 514K | 745K | 1.52M | 2.21M | 457K | 644K | 870K | 1.17M | 2.72M |
| Gross Profit | 250K | 117K | 352K | 175K | 880K | 1.12M | 244K | 320K | 331K | 614K | 1.10M |
| Operating Income | -1.52M | -2.13M | -1.50M | -2.17M | -1.11M | -1.37M | -2.49M | -1.70M | -2.27M | -3.13M | -3.01M |
| EBITDA | -1.40M | 1.81M | -1.81M | -1.68M | 6.31M | 6.51M | 2.75M | -1.84M | -2.06M | -2.93M | -2.59M |
| Net Income | -1.30M | 1.91M | -1.92M | -2.37M | 5.80M | 6.26M | 2.59M | -2.04M | -1.81M | -3.89M | -6.29M |
| EPS | -0.02 | 0.02 | -0.02 | -0.03 | 0.06 | 0.07 | 0.03 | -0.02 | -0.02 | -0.04 | -0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 5.66M | 7.67M | 8.03M | 6.79M | 13.7M | 20.1M | 11.5M | 9.40M | 9.05M | 6.89M | 5.17M |
| Total Liabilities | 660K | 623K | 967K | 1.81M | 1.85M | 1.97M | 643K | 532K | 647K | 610K | 442K |
| Shareholders' Equity | 4.91M | 7.04M | 7.03M | 4.95M | 11.8M | 18.1M | 10.9M | 8.87M | 8.40M | 6.28M | 4.73M |
| Cash & Short-term Investments | 3.12M | 1.25M | 1.32M | 456K | 865K | 2.01M | 1.05M | 635K | 739K | 1.04M | 989K |
| Total Debt | - | - | - | 727K | 772K | 819K | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.25M | -1.75M | -1.23M | -1.72M | -928K | -1.56M | -1.11M | -1.53M | -1.77M | -1.77M | -3.34M |
| Capital Expenditure | 10.6K | 1.80K | 2.95K | 595K | 350K | 194K | 168K | 0.00 | 0.00 | 1.77M | 0.00 |
| Free Cash Flow | -1.26M | -1.76M | -1.24M | -2.32M | -1.28M | -1.76M | -1.28M | -1.53M | -1.77M | -1.77M | -3.34M |
| Ratios | |||||||||||
| ROE | -26.4% | 27.1% | -27.3% | -47.9% | 49.1% | 34.5% | 23.7% | -23.0% | -21.5% | -61.9% | -133.1% |
| ROA | -22.9% | 24.9% | -23.9% | -34.9% | 42.3% | 31.1% | 22.4% | -21.7% | -20.0% | -56.4% | -121.7% |
| Net Profit Margin | -450.5% | 998.0% | -373.1% | -317.9% | 381.0% | 282.9% | 566.1% | -316.6% | -207.5% | -333.6% | -231.5% |
| Debt to Equity | - | - | - | 0.15x | 0.07x | 0.05x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
OptiBiotix Health Plc dividends
OptiBiotix Health Plc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:200 on Aug 5, 2014.
Who owns OptiBiotix Health Plc
- Insiders 11.35%
- Institutions 7.72%
- Public & others 80.94%
- Shares outstanding 103M
- Free float 92.6M
OptiBiotix Health Plc company profile
- Company name
- OptiBiotix Health Plc
- Ticker
- OPTI.LSE
- ISIN
- GB00BP0RTP38
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 9
- Fiscal year end
- December
- Address
- Innovation Centre, York, United Kingdom, YO10 5DG
- Website
- optibiotix.com
About OptiBiotix Health Plc
OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential health benefits. Its first-generation products include Slimbiome, which offers a scientifically supported, non-pharmaceutical approach to reduce hunger and cravings; and WellBiome a novel in vitro model of the human gut. In addition, the company offers second-generation solutions, including Sweetbiotix which are dietary fibres used as an alternative to sugar and existing sweeteners; and Microbiome Modulators. Further, it provides CholBiome, a food supplement for reducing cholesterol and blood pressure and supporting vascular health; OptiBiotics, a portfolio of prebiotics developed to target and enhance the growth of specific probiotics; and SlimBiome X3, a supplement that helps users cut calories without hunger and cravings. The company was formerly known as Ducat Ventures PLC and changed its name to OptiBiotix Health Plc in August 2014. OptiBiotix Health Plc was incorporated in 2006 and is headquartered in York, the United Kingdom.
OptiBiotix Health Plc management
4- Mr. Stephen Patrick O'HaraFounder, CEO & Executive Director · born 1960
- Mr. David Jonathan Blain ACACFO, Finance Director, Company Secretary & Director · born 1961
- Dr. Sofia KolydaExecutive Director of Research & Development and Executive Director · born 1973
- Paul CanningsHead of Operations & Quality